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Abstract
Background Anorexia, body wasting, inflammation, muscle, and adipose tissue loss are hallmarks of cancer cachexia, a syn-
drome that affects the majority of cancer patients, impairing their ability to endure chemotherapeutic therapies and reducing
their lifespan. In the last 10 years, alterations of protein turnover and impairment of adult myogenesis have been proposed as
major contributing factors.
Methods Muscle stem cells, including satellite cells, mesoangioblasts, and fibroadipogenic progenitors, were isolated and
characterized from C26 colon carcinoma-bearing (C26) mice. Circulating levels of interleukin-4/13 (IL4/IL13) were analysed
by ELISA, and the effects of IL4 on muscle mass and function, protein synthesis, muscle regeneration, and myogenic progenitor
cell number were analysed at both functional (treadmill and grip test) and molecular levels (qRT–PCR, immunofluorescence
analysis, surface sensing of translation, and western blot). The Kaplan–Meier test was used to analyse the survival curve of
IL4-treated and IL4-untreated C26 mice.
Results The administration of IL4 to C26 mice rescued muscle mass by increasing protein synthesis. The IL4 treatment im-
proved performances and prolonged survival of C26 mice. IL4 administration re-established both number and function of sat-
ellite cells and fibroadipogenic progenitors without affecting mesoangioblasts in C26 mice, rescuing myogenesis. Upon IL4
treatment, a high number of cytotoxic lymphocytes and type II macrophages were observed with a subsequent increase in
necrotic areas of C26 tumours.
Conclusions The results here presented shed new light on IL4 signalling during muscle wasting and early stages of muscle
regeneration that explain the beneficial effect observed in IL4-treated C26mice. These findings might aid to develop therapeu-
tic approaches to improve mobility and quality of life in cachectic patients.
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Introduction
Cachexia is a multifactorial syndrome associated to many
types of cancers, affecting mainly gastrointestinal tract and
lungs, that compromises absorption of nutrients and de-
creases the possibility for the patients to efficiently breathe.1
The occurrence of cachexia increases chemotherapy toxicity,
complicates patient management, and enhances mortality
rates, accounting for about 20% of cancer deaths worldwide
(Cancer fact sheet, World Health Organization 2017; https://
www.who.int/news-room/fact-sheets/detail/cancer).
Loss of muscle, with or without loss of fat mass, is one of the
main hallmarks of the cachectic phenotype, is not reversed by
nutrient supplementation, and, at least in experimental model
systems, is mainly associated with the hyperactivation of cata-
bolic signals involving the main proteolytic systems.2–4 In addi-
tion, protein synthesis is altered in favour of degradation and
cannot be restored in experimental models by forcing the ac-
tivity of anabolic pathways.5 Cytokines and pro-inflammatory
signals produced by the host immune system interact with
the tumour, contributing to generate insulin and other growth
factors resistance in the muscle of cancer patients. Consis-
tently, drugs able to enhance muscle anabolism and to in-
crease appetite and energy storage, such as several ghrelin
mimetics, have entered in phase II clinical trials.6
In the last decade, different groups have proposed that
also impaired myogenesis could contribute to cancer-induced
muscle wasting. In this regard, in the muscle of tumour-
bearing animals, satellite cells (SCs) increase in number and ac-
cumulate in the interstitial space among the fibres.7,8 The
same pattern has been observed also in cancer patients.8,9
From the mechanistic point of view, activation of NF-κB in
myogenic progenitors has been pointed as responsible for a
persistent up-regulation of PAX7, thus blocking the expression
of transcription factors important for SC differentiation.8
This myogenic impairment can be partially removed by treat-
ment with MEK inhibitors.7 Another study has shown the oc-
currence of a defect in muscle stem cell proliferation and
differentiation in cachectic animals, which has been associated
with decreased number of macrophages and mesenchymal
progenitors.10
Several studies have clarified that, in addition to SCs, also
other cell types can contribute to myogenesis, such as
mesoangioblasts (MABs), vessel-associated muscle progeni-
tors, and fibroadipogenic progenitors (FAPs). Consistently, re-
cent data from our group have demonstrated that BMP-SMAD
signalling blockade improves MAB myogenic differentiation.11
As for FAPs, they have been firstly described as non-myogenic
interstitial stem cells present in the adult muscle that upon in-
jury can drive SC differentiation through secretion of
interleukin-4 (IL4) and interleukin-13 (IL13).12,13 Indeed, these
cells have been reported to improve skeletal muscle regenera-
tion in acute14 and chronic conditions.15 On the other side,
IL4/IL4R and IL13/IL13R have been found highly up-regulated
in the skeletal muscle after exercise, suggesting an anabolic
role played by the two cytokines in this tissue.16 IL4 has also
been shown to recruit myoblasts to form mature myotubes,17
and further studies have demonstrated that this cytokine can
exert a pro-migratory effect in vitro.18 Interestingly, in pancre-
atic cancer patients affected by cachexia, IL4 messengers are
down-regulated in liver and muscle.19
The aim of the present study is to investigate the mecha-
nisms underlying the impaired myogenesis in cancer hosts, fo-
cusing on the role that interstitial cells and cytokines involved
in muscle differentiation might play in contributing to cancer-
induced muscle wasting.
Materials and methods
Animal experiments
All animal procedures20 were performed according to the
guidelines of the Animal Welfare Committee of KU Leuven
and Belgian/European legislation (P051/2017). Four-week-
old Balb/c mice of approximately 20 g were obtained from
Charles River Laboratories (Wilmington, MA, USA). Mice
were maintained on a regular dark–light cycle (light from
8 h a.m. to 8 h p.m.), with free access to food and water.
C26 colon-adenocarcinoma cells5 were maintained in high-
glucose Dulbecco’s modified Eagle’s medium (DMEM), sup-
plemented with 10% foetal bovine serum (FBS), 1 mg/mL
of sodium pyruvate, and 1 IU/mL of penicillin and strepto-
mycin. The plates were incubated at 37°C, 5% CO2, 5% O2,
and the medium was refreshed every 2 days. Tumour-
bearing mice were inoculated subcutaneously dorsally with
5 × 105 C26 carcinoma cells. The number of mice per group
depends on the experiments as it is indicated in the leg-
ends of the respective assays. Where indicated, 1.3 μg
per mouse intraperitoneal IL4 (Peprotech, Rocky Hill, NJ,
USA) was administered every day, starting from Day 5 to
the day of sacrifice.14 Multiple experiments were per-
formed with body weight, tumour size, and survival rates
recorded. The blood was collected through intracardiac in-
jection at the sacrifice, obtained through cervical disloca-
tion. After collecting the blood in heparin, centrifugation
at 845 g was performed to obtain the blood cells (fixed
with Thermo Fisher Scientific, 1-step Fix/Lyse Solution for
flow cytometry analysis), and the plasma was kept at
80°C for ELISA experiments. Animal weight and food in-
take were recorded daily. Tumour-bearing mice were
sacrificed under anaesthesia 13–14 days after tumour trans-
plantation. Several muscles and organs were rapidly ex-
cised, weighed, frozen in isopentane cooled with liquid
nitrogen, and stored at 80°C. Peritoneal lavage was per-
formed with 50 μM of EDTA in phosphate-buffered saline
(PBS) to extract lymphocytes and macrophages. Tumour
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tissue was digested for 90′ in 1 mg/mL collagenase II and
IV 1:1.
Four-month-old alpha-sarcoglycan (αSG)-null mice from
the internal colony of Sampaolesi laboratory were generated
by the group of K.P. Campbell (University of Iowa, IA, USA).21
Due to the absence of αSG from the muscle membrane, these
mice, starting from 2 to 3months of age, undergo continuous
cycle of muscle fibre degeneration and regeneration. For
these reasons, these mice were used to test the ability of C-
MABs and C26-MABs to contribute to muscle regeneration
upon cyclosporine immunosuppression (as already described
in Costamagna et al.11).
Survival experiment
Mice were followed until the KU Leuven predetermined hu-
mane endpoint criteria were fulfilled. Mice were ultimately
sacrificed when C26 cell inoculation determined body mass
loss above 20%, combined with an overall health status of se-
vere sufferance, food intake decrease, abnormal appearance
and posture (lack of grooming, piloerection, and hunched
posture), unnatural behaviour (impaired locomotion, inactiv-
ity, and reduced reactivity to external stimuli), and body tem-
perature below 28°C. During the experiment, mice were
separated to avoid self-mutilation.
Treadmill and muscle strength
Mice were introduced to the treadmill belt to test the condi-
tions before the actual test (motor speed set to zero, for 5
min). Later on, the motor speed was set to 10 m/min, with
a 1 m/min increase and an uphill inclination of 10°, till ex-
haustion and >10 s stop.11 Grip strength was measured with
digital grip strength metre (Columbus Instruments). Three
measurements with 10 min interval between tests were com-
pleted for each mouse.
Muscle injury
Mice received 50 μL injection of 10 μM solution of cardiotoxin
(CTX, Naja mossambica mossambica, Sigma-Aldrich) in the
tibialis anterior, the gastrocnemius, and the quadriceps of
one hind limb. The contralateral muscles were injected with
the same volume of PBS as a control. Ten days after the
in vivo regeneration experiments, the mice were sacrificed
by cervical dislocation, and muscles were processed for histo-
logical analysis. For the experiment of muscle injury in parallel
to the survival experiment (regenerating muscle shown in
Supporting Information, Figure S6b, n = 5 C26; n = 5 C26 +
IL4), mice were sacrificed when all the signs of severe suffer-
ance were reached and body temperature was below 28°C.
Surface Sensing of Translation (SUnSET)
experiment
In order to detect protein synthesis at the moment of the sac-
rifice, mice were administered intraperitoneally of 0.040
μmol/g puromycin (Sigma-Aldrich) and euthanized 30 min af-
ter injection.22 Muscles were rapidly removed, weighted, and
frozen in liquid nitrogen. Puromycin-conjugated peptides were
visualized by western blotting (WB) on a gradient gel by using a
mouse monoclonal anti-puromycin antibody (Table 2). The
density of each lane has been then measured by QuantityOne
software and normalized per aTubulin (Table 2) levels to deter-
mine the protein synthesis rate expressed as puromycin rela-
tive abundance.
Cell isolation and culture
Adult SCs were isolated by enzymatic digestion with 0.01%
collagenase D and 0.06% pancreatine during 90′ digestion of
minced murine muscle and pre-plated on 0.1% gelatin-coated
dishes to remove fibroblasts. Cells were counted and plated
on 0.1% collagen for experiments of cell proliferation in
high-glucose DMEM supplemented with 20% FBS, 1 mg/mL
of sodium pyruvate, 1 IU/mL of penicillin and streptomycin,
and 1 mg/mL of non-essential amino acids, 50 μg/mL of gen-
tamicin, and 1:100 chick embryo extract (Gentaur, Genprice
Inc., CA, USA). The plates were incubated at 37°C, 5% CO2,
5% O2, and the medium was refreshed every 2 days. Myo-
blast differentiation was obtained with the same medium as
for C2C12 differentiation. After tissue explant, adult
Mesoangioblasts (MABs) were sorted for ALP+ and induced
to express GFP (as for 11). After sorting, the GFP+ cells were
cultured on 0.1% collagen-coated dishes and maintained in
high-glucose DMEM supplemented with 20% FBS, 1 mg/mL
of sodium pyruvate, 1 IU/mL of penicillin and streptomycin,
and 1 mg/mL of non-essential amino acids. The plates were
incubated at 37°C, 5% CO2, 5% O2, and the medium was
refreshed every 2 days. Intramuscular injections of 2 × 105
murine GFP+ MAB or MAB cells pretreated for 48 h with 5
μM dorsomorphin (Sigma-Aldrich; DM-MABs) were per-
formed in αSG-null mice (n = 5 for each group). During the en-
tire treatment, mice were maintained with cyclosporine
(Sandimmune cyclosporine, Novartis; 10 mg/kg); 21 days
post-injection mice were sacrificed and compared with
sham-operated mice (saline solution injected).
C2C12myoblast cells were maintained at 37°C in 5% CO2 in
air-humidified chamber in high-glucose DMEM
with glutamine, supplemented with 10% FBS, 1 mg/mL of
sodium pyruvate, and 1% penicillin/streptomycin (Thermo
Fisher Scientific). When the cells reached confluency,
growth medium was replaced with differentiation medium,
supplementing high-glucose DMEM with 2% horse serum, 1 -
mg/mL of sodium pyruvate, and 1 IU/mL of
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penicillin/streptomycin. The plates were incubated at 37°C,
5% CO2, 5% O2, and the medium was refreshed every 2 days.
In order to efficiently knockdown IL4Ra and IL13Ra,
endoribonuclease-prepared siRNAs against IL4Ra and
IL13Ra (MISSION esiRNA Mouse Il4ra and MISSION esiRNA
Human IL13ra1; Sigma-Aldrich) were applied following the
manufacturer’s instructions. Briefly, C2C12 at Day 2 of
myotube differentiation was transfected using Lipofecta-
mine 2000 and Opti-MEM. At different time points after
transfection (24, 48, and 72 h), cells were lysed for RNA ex-
traction or WB analysis. RNA Mini Kit was used for RNA iso-
lation, and genomic DNA traces were removed with Turbo
DNase, following the manufacturer’s instructions; 500 μg
of RNA were reverse-transcribed with the SuperScript III
kit. The resulting cDNA was transferred in a 384-well plate
pre-filled with 250 nM primers. Platinum SYBER green mix
was added to a final volume of 10 μL per well. The RT–
qPCR was performed for 40 cycles (95°C, 15 s; 60°C, 45 s)
and read on a ViiA 7 qPCR plate reader. The list of murine
primers used is available in Table 1.
Flow cytometry analysis
Staining was performed with primary antibody (Table 2) dur-
ing 30′ at room temperature, and it was followed by 30′ sec-
ondary antibody staining (just for Ki67, Alexa Fluor 647,
Thermo Fisher Scientific) or from final washes. Fluorescence
minus one and compensations were included when neces-
sary for appropriate gating. Cells were analysed and quanti-
fied by flow cytometry (BD FACS Canto HTS; BD Biosciences),
and FlowJo Software was used to analyse the data (FlowJo
V10 LLC).
ELISA assay
IL4 and IL13 serum levels were detected by a commercially
available mouse ABTS-ELISA kit, used according to the manu-
facturer’s instructions (Peprotech). Serum from each animal
(50 μL) was assayed in triplicate. Quantitative calibration was
obtained performing a standard curve with recombinant
mouse IL4 and IL13.
Immunofluorescence
Tissues (7 μm muscle tissue and 5 μm tumour tissue) and
cells were fixed with 4% paraformaldehyde (Polysciences
Europe GmbH) in PBS and permeabilized with 0.2% Triton
X-100 in PBS containing 1% (w/v) bovine serum albumin
(BSA). A blocking solution containing donkey serum (1:10 di-
luted in PBS; VWR) was applied, and primary antibodies (Ta-
ble 2) were incubated overnight in PBS supplemented with
1% BSA. Secondary Alexa Fluor donkey antibodies were di-
luted at 4 μg/mL in PBS supplemented with 1% BSA, and
the nuclei were counterstained with 10 μg/mL Hoechst. Fluor
Save reagent (Millipore, Chemicon) was used as mounting
medium. Images were acquired using an Eclipse Ti inverted
microscope (Nikon).
Western blot
Western blotting analysis was performed on lysates from tis-
sue or cells in RIPA buffer (Sigma-Aldrich) supplemented with
10 mM sodium fluoride, 0.5 mM sodium orthovanadate,
1:100 protease inhibitor cocktail (Sigma-Aldrich), and 1 mM
phenylmethylsulfonyl fluoride. Equal amounts of protein (40
μg) were heat-denatured in sample-loading buffer (50 mM
Tris–HCl, pH 6.8, 100 mM DTT, 2% SDS, 0.1% bromophenol
blue, 10% glycerol), resolved by SDS-polyacrylamide gel elec-
trophoresis, and then transferred to nitrocellulose mem-
branes (Protran, nitrocellulose membrane, Amersham). The
filters were blocked with Tris-buffered saline containing
0.05% Tween and 5% non-fat dry milk (Sigma-Aldrich) and
then incubated overnight with the indicated dilutions of differ-
ent primary antibodies (Table 2). All secondary horseradish
peroxidase-conjugated antibodies (BioRad) were diluted
1:5000 in Tris-buffered saline-Tween and 2.5%non-fat drymilk
(Sigma-Aldrich). After incubation with SuperSignal Pico or
Femto chemiluminescence substrate (Thermo Scientific), the
polypeptide bands were detected with GelDoc chemilumines-
cence detection system (BioRad). Quantification of relative
densitometry was obtained by normalizing vs. background
and housekeeping proteins using the QuantityOne software
(BioRad).
Table 1 List of the primers used in this study
IL13 fw CAGCCTCCCCGATACCAAAAT
IL13 rev GCGAAACAGTTGCTTTGTGTAG
IL13R fw ATGCTGGGAAAATTAGGCCATC
IL13R rev ATTCTGGCATTTGTCCTCTTCAA
IL4 MC13 fw GGTCTCAACCCCCAGCTAGT
IL4 MC13 rev CCCTTCTCCTGTGACCTCGT
IL4R fw GAATAGGCCGGTCCAATCAGA
IL4R rev CAGCCATTCGTCGGACACATT
Myomixer fw CTGAGCTGTCTGCTCTTTGT
Myomixer rev TCTCCTTCCTCTGGGAGTG
Myomaker fw CCTGCTGTCTCTCCCAAG
Myomaker rev AGAACCAGTGGGTCCCTAA
Myomerger-short fw CAGGAGGGCAAGAAGTTCAG
Myomerger-short rev ATGTCTTGGGAGCTCAGTCG
Myomerger-long fw ACCAGCTTTCATGCCAGAAG
Myomerger-long rev ATGTCTTGGGAGCTCAGTCG
Gapdh fw TGGTGAAGGTCGGTGTGAAC
Gapdh rev GCTCCTGGAAGATGGTGATGG
Tbp fw CAAACCCAGAATTGTTCTCCTT
Tbp rev ATGTGGTCTTCCTGAATCCCT
Hprt fw TGGATACAGGCCAGACTTTGTT
Hprt rev CAGATTCAACTTGCGCTCATC
4 D. Costamagna et al.
Journal of Cachexia, Sarcopenia and Muscle 2020
DOI: 10.1002/jcsm.12539
Statistical analysis
All results were expressed as mean ± standard deviation, with
the exception of gene expression (mean ± SEM). Representa-
tiveWBs were selected from independent experiments. When
data distribution approximated normality and two groups
were compared, a Student’s t-test was used. When three or
more groups were compared, a one-way analysis of variance
was used. In case of non-normal distribution of the data pools,
such as for statistical comparison of the differences between
percentage values, a Kruskal–Wallis one-way analysis of vari-
ance by rank test was used. All statistical tests were performed
via Prism software (GraphPad).
Results
Mice bearing the C26 tumour represent a well-characterized
system to study cancer cachexia.5 As previously reported, 14
days after C26 cell implantation, body weight in tumour-
bearing mice was about 75% of that observed in control ani-
mals (C; body weight at Day 0 = 20.41 ± 1.89 g; Figure 1A). A
comparable reduction (about 25% lower than C values) was
observed for several muscles, namely, tibialis anterior, gas-
trocnemius, and quadriceps (Figure 1B).
Muscle stem cells isolated from C26 hosts: in vitro
proliferation and differentiation
The number of SCs isolated frommuscles of C26 hosts (hereaf-
ter C26-SCs) was higher than that obtained from C muscles (C-
SCs; Figure 1C). Consistently, 4 days after plating, C26-SC cul-
tures displayed a higher number of clones than C-SC ones (Fig-
ure 1D), demonstrating that the proliferative ability was higher
in C26-SCs than in C-SCs. In immunofluorescence analysis,
both C26-SCs and C-SCs showed positivity for PAX7 andMyoD,
confirming in vitro their myogenic lineage (Figure 1E, left
Table 2 List of the antibodies used in this study for western blot (WB), immunofluorescence (IF), fluorescence-activated cell sorting (FACS) and Flow
Cytometry analyses
Antibody Provider WB IF FACs
PE Ms Human/Mouse/Rat Alkaline Phosphatase MAb (Cl B4-78) R&D Systems 2.5 μg/106
FITC rat anti-mouse CD11b BD Pharmigen 1 μg/mL
APC F4/80 Monoclonal (BM8) Thermo Fisher Scientific 1 μg/mL
Brilliant Violet 421 anti-mouse CD206 (C068C2) BioLegend 1 μg/mL
APC anti-mouse CD3 BioLegend 1 μg/mL
APC/Cy7 anti-mouse CD4 (Cl GK1.5) BioLegend 1 μg/mL
PerCP/Cy5,5 anti-mouse CD8a BioLegend 1 μg/mL
PE-anti-mouse CD25 BioLegend 1 μg/mL
APC Ly-6A/E (Sca-1) Monoclonal (D7) Thermo Fisher Scientific 1 μg/mL
PE-Vio770-Anti-mouse Integrin a7 (Cl 3C12) Miltenyi Biotech 1 μg/mL
Ms anti-human/Mouse/Rat Ki67 (Cl B56) BD Pharmigen 1:300 1 μg/mL
Goat GFP (ab5450) Abcam 1:500
Rabbit GFP Thermo Fisher Scientific 1:300
Mouse Human/Mouse/Rat MF20 DSHB 1:3 1:10
Mouse Human/Mouse/Rat eMyHC DSHB 1:3 1:10
Mouse Human/Mouse/Rat PAX7 DSHB 1:3 1:10
Mouse Human/Mouse/Rat Myogenin (DH5) DSHB 1:3 1:10
Mouse PDGF R alpha R&D Systems 1:100
Anti-Mannose Receptor (15-2) (ab8918) Abcam 1:200 1:100
Anti-F4/80 [CI:A3-1] (ab6640) Abcam 1:100 1:50
Rabbit Mouse P-Akt Cell Signaling 1:500
Rabbit Mouse Akt Cell Signaling 1:1000
Rabbit P-p70 Cell Signaling 1:1000
Mouse p70 Cell Signaling 1:1000
Rabbit JNK Cell Signaling 1:1000
Rabbit P-p38 Cell Signaling 1:1000
Mouse p38 Santa Cruz Biotech 1:200
Mouse p-ERK Santa Cruz Biotech 1:200
Rabbit ERK Santa Cruz Biotech 1:200
Mouse ESGP Antibody AF4580 R&D Systems 1:3000 1:1000
Rabbit IL4Ra (SAB4501541) Sigma-Aldrich 1:200
Rabbit TRIM63 Antibody (SAB1411517) Sigma-Aldrich 1:500
Rabbit Beclin1-BH3 Domain (SAB1306537) Sigma-Aldrich 1:1000
Rabbit LC3B Antibody (L7543) Sigma-Aldrich 1:1000
Mouse p62 BD Biosciences 1:10 000
Atrogin1 (AP 2041) ECM Biosciences 1:200
Mouse Human/Mouse/Rat aTubulin Sigma-Aldrich 1:1000
Rabbit Human/Mouse/Rat GAPDH Sigma-Aldrich 1:1000
Mouse Puromycin MABE343 (Cl 12D10) Merk Millipore 1:1000
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Figure 1 Characterization of control (C) and C26 muscle stem cells. (A) Body weight loss of C (n = 6) and C26 mice (n = 8) during 14 days of tumour
growth, expressed as percentage of initial body weight. (B) Tibialis anterior (TIB; C: 98 ± 5.9 mg/100 g i.b.w.), gastrocnemius (GSN; C: 280.5 ± 19 mg/
100 g i.b.w.), and quadriceps (QD; C: 396 ± 29 mg/100 g i.b.w.) muscle weight from C and C26, expressed as percentage of the initial body weight. (C)
BF images (on the left) and quantification (on the right) of satellite cells (SCs) extracted from C-specific and C26-specific muscles. (D) Representative SCs
clones (on the left) and quantification (on the right) from C and C26, 4 days after seeding. (E) IF of SCs from C and C26 stained for PAX7 (red) and MyoD
(green; column on the left = Day 0 of differentiation), or MyHC (red) and MyoD (green; column on the right = Day 2 of differentiation). (F) BF images of
MABs isolated (column on the left) from C and C26 muscle explants after 7 days of organ culture and stained for ALP (column on the right). Quanti-
fication of C-MABs and C26-MABs (graph on the right). (G) GFP+ C-MABs and C26-MABs (column on the left), BF overlapped with fluorescent images of
the same cells with C2C12 in co-culture (middle column). IF for MyHC (red) and GFP (green) on GFP+ C-MABs and C26-MABs in co-culture with C2C12
after 5 days of differentiation medium (column on the right). (H) Transversal sections of TIB from αSG-null mice injected with GFP+C-MABs or GFP+C26-
MABs (column on the right) or with the same cells pretreated during 48 h with dorsomorphin (5 μM, DM), before the injection. Quantification (on the
right) of the percentage of GFP
+ αSG+ fibres in the injected muscles. (I) C and C26 populations of adipocyte-like cells were stained with Oil-Red-O (col-
umn on the left) and perilipin (PLIN1; column on the right). Nuclei were stained with HOECHST (blue). Plasma levels for (J) IL4 (pg/mL) and (K) IL13 (pg/
mL) cytokines in C and C26 mice. Significance of the differences: *P < 0.05, **P < 0.01, ***P < 0.001 vs. C. Scale bar: 500 μm.
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panels). When exposed to differentiation medium, these cells
were able to activate the differentiation programme, fusing
into multinucleated myotubes and expressing both MyoD
and MyHC (Figure 1E, right panels), or ACTN2 (Supporting In-
formation, Figure S1a). The expression of terminally differenti-
ated myotube markers let us conclude that ex vivo C26-SCs
behave comparably with C-SCs.
Similarly, MABs sorted as alkaline phosphatase (ALP)-posi-
tive cells (Figure 1F) were isolated from the skeletal muscle
of C26 hosts in higher number than in C mice (Figure 1F, quan-
tification). To evaluate the ability of MABs to contribute to
muscle differentiation, C-MABs and C26-MABs were
transfected to express GFP (Figure 1G, left panels) and co-
cultured with C2C12myoblasts. After 5 days of differentiation,
GFP-expressing multinucleated myotube-like structures ap-
peared (Figure 1G, central panels). MyHC+ and GFP+ myotubes
were detected in both C-MABs and C26-MABs co-cultures,
demonstrating that GFP+MABs were able to fuse with C2C12
myotubes (Figure 1G, right panels; Supporting Information,
Figure S1b and S1c). In order to test if C-MABs and C26-MABs
display the same ability in vivo, these cells were injected intra-
muscularly into αSG-null mice.11 Twenty-one days after C-MAB
and C26-MAB injection, the muscle of αSG-null mice showed
the presence of GFP+ fibres expressing αSG, clearly originated
from the fusion of the injected C-MABs and C26-MABs (Figure
1H, left panels). Moreover, as previously described,11 both en-
graftment and differentiation were further improved when
injected C-MABs and C26-MABs were pretreated in culture
for 48 hwith 5 μMdorsomorphin (DM), in order to inhibit type
I BMP receptor complex and obtain a proliferation arrest, fi-
nally promoting differentiation (Figure 1H, right panels and
quantification). Taken together, these results confirm that
the myogenic properties of MABs isolated from C26 hosts
are not impaired.
Finally, the majority of interstitial muscle cells, isolated
from the muscle of C26-bearing mice and put in culture, dif-
ferentiated to adipocyte-like cells, a pattern that was not ob-
served in cultures prepared with cells isolated from C
muscles. Increased PLIN1 expression of Oil-Red-O-positive
cells (Figure 1I, right panel) and the positive bright field stain-
ing for Oil-Red-O (Figure 1I, left) confirmed the acquisition of
an adipocyte-like phenotype in vitro.
These data demonstrate that the impaired myogenesis oc-
curring in the C26 hosts does not result from a stem
cell autonomous defect but is rather related to the micro-
environment these cells are exposed to. The hypothesis is
that tumour-induced modulations of muscle micro-
environment do not allow stem cell differentiation. On the
basis of the adipogenic drift observed when cells isolated
from the muscle of C26 hosts were put in culture, the possi-
bility that myogenic relevant cytokines14 could be perturbed
was assessed. Data available in literature have stressed the
importance of IL4 and IL13 during the first phases of muscle
regeneration; thus, we evaluated their expression in both
muscle and blood from C and C26 hosts. Quantitative qRT–
PCR showed in muscle tissues from C26-bearing mice a signif-
icant increase of IL4Ra and a decrease in IL13 transcript
levels, with respect to control values, while no significant dif-
ferences could be observed for both IL4 and IL13R mRNAs
(Supporting Information, Figure S1d). The low availability of
efficient antibodies for WB let however any conclusion on
the expression of these molecules still at a speculative level.
Finally, while circulating IL4 was comparable in both C26
hosts and C mice (Figure 1J), IL13 plasma levels were signifi-
cantly lower in the former than in the latter (Figure 1K).
Interleukin-4 treatment improves cachexia in
tumour-bearing mice
The data reported earlier suggested that IL4/IL13 signalling
was affected in the C26 hosts. The next step of the study
was to investigate if potentiating such signalling could improve
impaired regeneration and cachexia in the C26 hosts. The
choice to use IL4 instead of IL13, as it could be expected
looking at their circulating levels in the C26 hosts, was based
on the observation that IL4 exerted its bioactivity engaging
both its own receptor and the IL13 receptor (reviewed in Wu
et al.23, thus providing a rather complete spectrum of action
on the signalling pathways depending on both cytokines.
Along this line, C26-bearing mice were treated with IL4
after having excluded, by in vitro experiments, the possibility
that IL4 could exert a direct effect on tumour cells
(Supporting Information, Figure S2a). Starting from Day 5 after
C26 inoculation, IL4 was administered intraperitoneally daily.
IL4 absorption curve in treated control mice confirmed high
circulating levels of the cytokine during the first 3 h after ad-
ministration, followed by a reduction to control values, ap-
proximately 8 h after IL4 injection (Supporting Information,
Figure S2b). Consistently, after 10 days of IL4 daily treatment,
circulating levels of the cytokine were significantly increased in
both C and C26 hosts (Figure 2B). To rule out the possibility of a
local response of the immune system to IL4 administration, in-
traperitoneal lavage and flow cytometry analysis were per-
formed. The results obtained showed, differently from what
observed in positive controls (LPS-injected mice; Supporting
Information, Figure S2e and S2h), comparable lymphocyte
(Supporting Information, Figure S2f and S2g) and macrophage
(Supporting Information, Figure S2i and S2j) percentages and
characteristics in IL4-treated and IL4-untreated C26 bearers.
No differences were as well reported comparing the perito-
neal lymphocytes and macrophages of IL4-treated mice,
confirming no effect at a peritoneal level after IL4 treatment
(data not shown).
As expected, body weight in the C26 hosts was lower than
in C (Day 0: 21.57 ± 1.07 g; 25% reduction), while it remained
comparable with Day 0 in tumour-bearing mice receiving IL4
(Figure 2A). In contrast, the reduction of food intake
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Figure 2 IL4 treatment counteracts muscle weight loss and fibre CSA, restores muscle performances, and prolongs survival of tumour-bearing mice.
(A) Percentage of body weight during 14 days after tumour injection in C26 (n = 6) and IL4-treated tumour-bearing mice (C26 + IL4, n = 6) was com-
pared with control (C, n = 4) and IL4-treated (IL4, n = 4) mice. (B) Plasma levels of IL4 (pg/mL) from C, C26, and daily treated IL4 and C26 + IL4mice. (C)
H&E staining (column on the left) of TIB muscles from the different groups with insets at a higher magnification (column on the right). (D) TIB (C: 105 ±
4 mg/100 g i.b.w.), GSN (C: 269 ± 7 mg/100 g i.b.w.), expressed as percentage of the initial body weight. (E) Fibre size distribution of TIB muscles. (F)
Grip test analysis, (G) running time, and (H) distance measured by treadmill exhaustion assay for C26 and C26 + IL4 and their controls group, C and IL4.
(I) Kaplan–Meier test for the significance of the difference between survival curve from C26 and C26 + IL4 attributed a P = 0.001 (n = 10 per group).
Significance of the differences: *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001 vs. C; +P < 0.05, ++P < 0.01, +++P < 0.001, ++++P < 0.0001 vs. IL4; $P
< 0.05,
$$
P < 0.01,
$$$
P < 0.001,
$$$$
P < 0.0001 vs. C26.
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occurring in the C26-bearing mice was not affected by IL4
treatment (mouse food intake on Day 13: C = 4.33 g; IL4 =
4.65 g; C26 = 1.45 g; C26 + IL4 = 1.88 g). Similarly, epididymal
fat pad was completely depleted in both C26 and C26 + IL4
groups with respect to controls (C = 2.01 ± 0.57; IL4 = 2.63
± 0.78 mg/100 g i.b.w.; C26 = ND; C26 + IL4 = ND; data are
expressed as mg/100 g i.b.w., P < 0.22 C vs. IL4). IL4 treat-
ment improved C26-induced muscle wasting in terms of both
muscle mass and cross-sectional area (CSA) stabilizing this lat-
ter to the level of C (Figure 2C–2E and Supporting Informa-
tion, Figure S2d). Because improved muscle mass or
myofiber CSA do not necessarily mean better muscle func-
tion, an additional experiment was performed to obtain func-
tional data. The results showed that grip strength was higher
in IL4-treated than in IL4-untreated C26 hosts reaching values
comparable with C mice (Figure 2F). Such improvement was
confirmed by an exhaustion treadmill assay, showing that
C26 hosts receiving IL4 run for longer time and distance than
untreated C26 mice, similarly to C mice (Figure 2G and 2H).
Finally, a survival experiment demonstrated that IL4-
treated C26-bearing mice were able to survive longer than un-
treated tumour hosts (31 days for C26 + IL4 vs. 13 days for C26;
Figure 2I).
Interleukin-4 treatment increases intratumour
cytotoxic lymphocytes and macrophages
The administration of IL4 to the C26 hosts resulted in in-
creased tumour mass (Supporting Information, Figure S2c)
that however does not necessarily reflect an increased num-
ber of tumour cells. Indeed, the H&E staining revealed that
more than 30% of tumour area in the IL4-treated C26-bearing
mice (sacrificed at Day 31 after C26 cell injection) was necrotic
(eosin positive) probably surrounded by small inflammatory
cell infiltrate, a pattern that could not be observed in tumours
isolated from C26 hosts (Day 13 after C26 implantation; Figure
3A and 3B).24 A possible limitation of these results is that the
histological analysis compares Day 13 C26 with Day 31 C26 +
IL4 tumours. However, because in the absence of IL4 treat-
ment the C26 hosts die at Day 13 after tumour implantation,
it was not possible to have untreated tumours at Day 31. Fu-
ture investigation will assess if the peculiar histological aspect
of C26 + IL4 tumours at Day 31 is already evident at Day 13.
IL4 treatment could contribute to stimulate the immune
system against tumour cells. To investigate this point, C26 tu-
mours from both IL4-treated (Day 31 after tumour transplan-
tation) and IL4-untreated (Day 13 after tumour
transplantation) animals were analysed in terms of lympho-
cyte and macrophage content. The results showed that the
percentage of cytotoxic lymphocytes (CD3+CD8+) and type II
macrophages (CD11b+, F4/80+, CD206+) was higher in tu-
mours from IL4-treated than IL4-untreated C26 hosts (cyto-
toxic lymphocytes: C26 = 13 ± 8%, C26 + IL4 = 25 ± 13%,
Figure 3C; macrophages: C26 = 27 ± 9%, C26 + IL4 = 37 ±
14%, Figure 3E). Consistently, the immunofluorescence indi-
cated that the borders of necrotic areas in tumours from
IL4-treated C26 hosts were as well positive for F4/80 and
CD206 (Figure 3D). Finally, the same analysis in the blood
(Supporting Information, Figure S3a and S3b) revealed a de-
creased percentage of circulating T-helper lymphocytes
(CD3+CD4+) in IL4-treated hosts.
Interleukin-4 administration improves protein
synthesis in tumour-bearing mice
The increased muscle mass and myofiber CSA could result
from both reduced protein degradation and increased pro-
tein synthesis rates. An experiment was performed to assess
this latter, by treating the animals with puromycin 30 min
before sacrifice.22 The results showed that muscle protein
synthesis is significantly improved in IL4-treated than in
IL4-untreated C26 hosts (Figure 4A and 4B). Such improve-
ment was associated with enhanced phosphorylation of Akt
and p70, as shown by WB analysis (Figure 4C–4E). Moreover,
the levels of P-JNK and P-ERK, this latter previously shown to
correlate with muscle wasting in C26 hosts,6 decreased in the
muscle of IL4-treated C26-bearing mice (Figure 4C, 4F, and
4G). On the other side, no significant differences among
treated and untreated C26 hosts could be observed as for
P-p38 levels (Supporting Information, Figure S4a and S4b)
and the state of activation of STAT3 and STAT6, both tran-
scription factors reported to transduce the signals dependent
on IL4Ra25,26 (Supporting Information, Figure S4c–S4e). In
addition, the main markers of proteolysis, such as Atrogin 1
and Trim 63 for the ubiquitin proteasome system (Supporting
Information, Figure S4f–S4h) and Beclin1 and LC3B for the
autophagic system (Supporting Information, Figure S4i–S4l),
were not affected by IL4 treatment. Differently, the levels
of p62-SQSM1 were lower in IL4-treated C26 mice when
compared with the untreated ones and similar to controls
(Supporting Information, Figure S4i and S4l–S4n).
Interleukin-4 treatment impinges on satellite cell
accumulation in the muscle of C26 hosts
To investigate if the beneficial effects induced by IL4 on mus-
cle mass and performance could also result from improved
myogenesis, we employed flow cytometry and established
gating strategies to identify the myogenic stem cells present
in the muscles of IL4-treated and IL4-untreated C26-bearing
mice. The total number of cells isolated from the muscle of
IL4-treated C26 hosts was comparable with controls and re-
duced with respect to untreated C26-bearing mice
(Supporting Information, Figure S5). As for the different mus-
cle stem cell populations, the results showed that SC number
was lower in C26 hosts administered with IL4 than in
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Figure 3 Tumour mass and flow cytometric analysis of tumour-associated immune cells. (A) H&E staining, (B) quantifications of the necrotic area (eo-
sin-positive area—white) on the cell-dense area (haematoxylin-positive area—grey) of tumour masses from C26 and C26 + IL4 mice (P < 0.01 vs. C26).
(C) Representative flow cytometry analysis and quantifications of the tumour digested cells from C26 and C26 + IL4 mice for the main markers of lym-
phocytes. (D) IF analysis of F4/80 and CD206markers and (E) flow cytometry analysis of the tumour digested cells from C26 and C26 + IL4 mice for the
same macrophage markers and quantifications. Significance of the differences: $P < 0.05, $$P < 0.01 vs. C26.
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untreated tumour-bearing animals (C26 = 17.1 ± 5.2%, C26 +
IL4 = 10.9 ± 2.0%; Figure 5A and 5B). This reduction was
paralleled by a significant decrease in PAX7 and myogenin
protein levels (Myog; Figure 5C–5E) and by an increased num-
ber of type II macrophages (Figure 5F–5H). While no differ-
ences were appreciated for MABs (C26 = 8.8 ± 2.6%, C26 +
IL4 = 8.8 ± 2.0%; Figure 5I and 5J), a trend to decrease, al-
though not significant, was shown for FAPs (C26 = 28.9 ±
5.1%, C26 + IL4 = 21.7 ± 5.3%; Figure 5K and 5L). Similarly, im-
munofluorescence analysis for PDGFRa (known markers for
FAP cells13) and Ki67 staining in C26 + IL4 muscle sections
showed a lower accumulation of cells when compared with
C26 ones (Supporting Information, Figure S5b). Consistently,
the number of PLIN1 and Oil-Red-O-positive cells was lower
in primary cultures obtained from the muscle of IL4-treated
vs. IL4-untreated C26-bearing mice (Figure 5M), suggesting
that interstitial FAPs in the former are less aberrant than in
the latter.
Interleukin-4 administration affects skeletal muscle
regeneration in C26-bearing mice
Previous studies reported that muscle regeneration is de-
layed in tumour-bearing mice.7,8 On the other side, IL4 treat-
ment was reported to improve muscle regeneration in
glycerol-injured animal model.17,27 Along this line, the myo-
genic response following CTX-induced muscle injury in the
C26 hosts, in the presence or in the absence of IL4 treatment,
was assessed. The results showed that regeneration is im-
proved by treatment with the cytokine (Figure 6A–6C). H&E
staining and quantification showed a decreased myofiber
CSA in CTX-C26 hosts and CTX-IL4 mice compared with CTX-
C (Figure 6D and 6F; Supporting Information, Figure S6a). In
CTX-C26 hosts treated with IL4, myofibers were smaller than
in the CTX-C26-bearing mice. This reduction in size, however,
is counterbalanced by an increase in number of newly gener-
ated fibres with low CSA (diameter between 0 and 1000 μm2:
Figure 4 IL4 treatment is associated to rescue of muscle synthesis. (A) WB for puromycin (Puro) incorporation in newly synthetized muscle proteins
from C, IL4, C26, and C26 + IL4 muscles was normalized on the levels of tubulin (aTub) levels and (B) quantified. (C) WB and (D) quantifications of P-
AKT, (E) P-p70, (F) P-JNK, and (G) P-ERK levels normalized for the total protein levels and on aTub expression levels. Significance of the differences is
reported as *P < 0.05, **P < 0.01, ***P < 0.001 vs. C, ****P < 0.0001; +P < 0.05, ++P < 0.01, ++++P < 0.0001 vs. IL4; $P < 0.05, $$P < 0.01, $$$$P <
0.0001 vs. C26.
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Figure 5 IL4 treatment counteracts muscle SC accumulation and decreases the levels of FAPs. After sacrifice and tissue digestion, muscle stem cells
were analysed by flow cytometry for the expression of different markers of SCs (Itga7 and CD34) (A) and consequently (B, D, F) quantified. (C) The
levels of PAX7 and myogenin (Myog) were analysed by WB, and (D, E) correspondent quantifications are reported on the right. (F) Protein levels of
F4/80 and CD206 and (G, H) correspondent quantifications. (I) Flow cytometry analysis for the expression of markers for MABs (ALP); (I, J) quantifica-
tion or for FAPs (Sca1) (K) and (L) quantification in C, IL4, C26, and C26 + IL4muscles. (M) Populations of adipocyte-like cells were stained with Oil-Red-
O (red) and perilipin (PLIN1; green). Nuclei were stained with HOECHST (blue). Significance of the differences: *P< 0.05, **P< 0.01, ***P< 0.001, ****P
< 0.0001 vs. C;
+
P < 0.05,
++
P < 0.01,
+++
P < 0.001,
++++
P < 0.0001 vs. IL4;
$
P < 0.05,
$$
P < 0.01 vs. C26.
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C26 = 38%, C26 + IL4 = 78%; Figure 6D and 6F and Supporting
Information, Figure S6a). Consistently, in muscles from CTX-
C26 hosts exposed to IL4, the levels of embryonic myosin
heavy chain (eMyHC) were similar to CTX-C or CTX-IL4 mus-
cles and lower than observed in muscles from CTX-C26 hosts
(Figure 6E, 6G, and 6H). Finally, in the injured muscle of C26
hosts treated with IL4 and analysed around 25–31 days after
injury, the number of mature fibres characterized by periph-
eral nuclei was higher than in untreated injured C26-bearing
mice (that died 13 days after tumour transplantation and 8
days after CTX injury; Supporting Information, Figure S6b).
No differences could be observed in both PAX7 and Myog ex-
pressions in both IL4-treated and IL4-untreated injured C26
hosts, although Myog levels showed a trend to decrease that
did not reach significance (Figure 6I–6K). Finally, muscle type
II macrophages were higher in CTX-C26 hosts than in CTX-
C26-bearing mice exposed to IL4 (Figure 6L–6N).
Interleukin-4 directly stimulates myocyte
differentiation
To better understand the response of muscle stem cells to IL4,
we first analysed the effects of IL4 on C2C12myoblasts in pro-
liferating conditions. Staining for Ki67 revealed an anti-
proliferative effect when 10 ng/mL IL4 were administered for
48 h to C2C12 myoblast cultures (Figure 7A). These results
were confirmed by flow cytometry analysis and quantification
(Figure 7B and 7C). In addition, IL4 was also able to reduce the
stimulation of C2C12 myoblast proliferation induced by treat-
ment with 100 ng/mL TNFα, a pro-inflammatory cytokine
known to inhibit C2C12 differentiation (Figure 7B and 7C).
These observations suggested that IL4 could impact on
C2C12 differentiation.15 To clarify this point, IL4/IL4Ra and
IL13/IL13RmRNA levels were assessed at Days 0 and 5 of myo-
genic differentiation (Supporting Information, Figure S7a). As
for protein, while IL4Ra levels were not detectable at Day 2
of differentiation (Supporting Information, Figure S7b), at
Day 5, when completely differentiated myotubes were ex-
pressing MyHC, IL4Ra became detectable (Figure 7D–7F).
When myotubes were exposed to 100 ng/mL TNFα during 5
days, a decrease in MyHC and in IL4Ra was reported. Such
changes were not rescued by co-treating myotubes with both
TNFα and IL4. This pattern was maintained even if TNFα levels
were reduced (50 ng/mL) and IL4 concentrations were in-
creased (100 ng/mL IL4, Supporting Information, Figure S7c
and S7d; 200 ng/mL IL4, Supporting Information, Figure S7e
and S7f).
To better understand the role of the IL4-dependent signal-
ling in C2C12 differentiation, loss-of-function experiments
were performed. IL4Ra was transiently silenced in differentiat-
ing C2C12. Interestingly, qRT–PCR data showed that the loss of
IL4Ra can be compensated by IL13Ra. Indeed, when IL4Ra was
down-regulated, the levels of IL13Ra increased, likely
compensating the missing IL4Ra (Supporting Information, Fig-
ure S7g). The other way around, when down-regulating
IL13Ra, IL4Ra levels increased (Supporting Information, Figure
S7h), confirming our interpretation. IL4Ra silencing decreased
transcript levels of genes promoting myoblast fusion,28–30
such as Myomixer (Mymx), Myomaker (Mymk), and
Myomerger-Minion (here indicated as Gm7325, analysed as
short version and long version at the transcriptional level), to
values lower than that of control cultures (Supporting Infor-
mation, Figure S7i). Therefore, to obtain a more effective abol-
ishment of IL4/IL13 signalling pathway, we induced a transient
IL4Ra and IL13Ra esiRNA double down-regulation in C2C12 in-
duced to differentiate. The results confirmed that while in con-
trol C2C12 myotubes reached a complete differentiation, as
shown by MyHC expression, transfected cells did not (Figure
7G–7J). Moreover, the protein levels of Myomerger (known
also as embryonic stem cell and germ cell-specific protein,
ESGP) were reduced, confirming that the lack of IL4/IL13 sig-
nalling impaired myoblast fusion (Figure 7K–7M). Finally, WB
analysis for ESGP protein levels in regenerating muscles from
C26-bearing mice did show similar levels in both IL4-treated
and IL4-untreated CTX-C26 hosts (Supporting Information, Fig-
ure S7j and S7k), suggesting that the delayed regenerative re-
sponse observed in IL4-treated vs. IL4-untreated C26 hosts
does not rely on impaired fusion.
Discussion
The present study shows for the first time that cancer-induced
muscle wasting is associated with increased number of differ-
ent muscle stem cell populations that cannot complete differ-
entiation in vivo despite maintaining their intrinsic myogenic
potential. Indeed, they are able to form mature myotubes
when isolated from the cancer host micro-environment. These
results agree with previous data showing the accumulation of
SCs in C26-bearing mice.7,8 The present results extend the
analysis to MABs that, similarly to SCs, increase in number
in the muscle of C26 hosts. These cells maintain the ability to
fuse with existing myofibers when exposed to permissive
regenerating conditions such as those occurring in the αSG-
null mice and are still able to respond to dorsomorphin.11
Taken together, these results highlight that stem cell number
and their intrinsic myogenic differentiation ability are not the
limiting factor contributing to muscle wasting in cachectic
tumour-bearing mice. In contrast, muscle interstitial stem cells
seem to miss the input to differentiate. In this regard, myo-
genic differentiation is physiologically regulated by FAPs, a
muscle stem cell population dependent on eosinophil granulo-
cyte secretion of IL4 and IL13.14 When isolated from the mus-
cle of the C26 hosts and put in culture, FAP cells degenerate to
adipocyte-like cells showing an adipogenic shift able to persist
in vitro and probably suggesting an intrinsic modification of
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Figure 6 IL4 treatment induces a higher number of precursors to be activated after cardiotoxin (CTX)-induced injury. In regeneration conditions, after
10 days from CTX-induced muscle injury, (A) TIB (C: 97 ± 6mg/100 g i.b.w.), (B) GSN (C: 262 ± 12mg/100 g i.b.w.), and (C) QD (C: 369 ± 14mg/100 g i.b.
w.) muscle weights, expressed as percentage of the initial body weight. (D) H&E staining (column on the left) with insets from the different muscles
(column on the right). (E) Representative IF muscle staining for Lam (purple) and eMyHC (green). Nuclei were stained with HOECHST (blue). (F) Fibre
size distribution of TIBmuscles from the different groups. (G) WB for eMyHC and (H) quantification. (I) PAX7, Myog protein levels with a representative
Gapdh and their (J, K) quantifications. (L) Protein levels of F4/80 and CD206 in the same muscles have been as well quantified in (M) and (N). Signif-
icance of the differences is reported as
***
P < 0.001,
****
P < 0.0001 vs. C;
++
P < 0.01,
++++
P < 0.0001 vs. IL4;
$
P < 0.05,
$$
P < 0.01,
$$$$
P < 0.0001 vs.
C26; £P < 0.05 vs. CTX IL4; #P < 0.05, ##P < 0.01 vs. CTX C26; ^P < 0.05, ^^P < 0.01, ^^^P < 0.001 vs. C26 + IL4.
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Figure 7 IL4 on C2C12 reduces the TNFα-induced proliferative effect and is essential for myotube differentiation. (A) IF, (B) flow cytometry analysis,
and (C) quantification of Ki67+ C2C12 cells treated with 10 ng/mL IL4, 100 ng/mL TNFα, or a combination of the two cytokines (TNFα + IL4) during 48 h
of proliferating medium. (D) WB and (E) quantifications of the protein levels of MyHC and IL4R1a normalized for aTub after 10 ng/mL IL4 or 100 ng/mL
TNFα or a combination of the two (TNFα + IL4) treatments during all C2C12 differentiation period (5 days differentiating medium). (F) IF for MyHC (red)
on C2C12 during the three last days of differentiation (24 h = Day 3 of differentiation, 48 h = Day 4 of differentiation, 72 h = Day 5 of differentiation)
after the double IL4Ra and IL13Ra silencing. HOECHST (blue) was used to stain nuclei. (G) WB and (H, I) quantifications for MyHC and IL4Ra protein
levels normalized for aTub after double IL4Ra and IL13Ra silencing. (J) IF, (K) WB, and (L) quantification for the levels of ESGP (Myomerger) normalized
on the ones of Gapdh that were analysed in the same cells silenced for IL4Ra and IL13Ra. Significance of the differences:
*
P < 0.05,
**
P < 0.01,
***
P <
0.001 vs. C; +P < 0.05, ++P < 0.01, +++P < 0.001 vs. IL4.
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these cells. Modulations of muscle IL4/IL4R and IL13/IL13R, as
well as of IL4 and IL13 plasma levels, showed that the signalling
dependent on these cytokines is likely altered in the C26-
bearing mice, supporting the possibility of improper FAP be-
haviour and functions. In this regard, an intriguing hypothesis
is that FAP degeneration to adipocyte-like phenotype could
contribute to myosteatosis, a common feature in patients af-
fected by chronic inflammation and cachexia.31,32 A detailed
analysis of muscle biopsies obtained from cancer patients re-
ported intramyocellular lipid droplets and large accumulation
of neutral lipids in connective tissues in the rectus
abdominis.33 Further studies are required to understand the
nature of this phenomenon and to clarify if related to the ex-
cessive adipogenic differentiation of FAP cells that we report
in C26 mice. In this regard, the lack of myosteatosis in the
C26 hosts could be due to the short time interval between tu-
mour implantation and animal sacrifice. Finally, altered FAP-
dependent signalling might also explain the impaired
myogenesis occurring in tumour-bearing mice (see succeeding
text).
Along this line, the results of the present study show for
the first time that IL4 administration to mice bearing the
C26 tumour improves cachexia in terms of body weight, mus-
cle mass, and function. Moreover, IL4-treated C26-bearing
mice can survive 20 days longer than untreated C26 hosts.
Similarly, increased survival was previously obtained by
injecting intraperitoneally a plasmid encoding for IL4 in mice
bearing an ascitic form of the C26 tumour.34 The effective-
ness of IL4 administration in C26 hosts relies, partially at
least, on the promotion of protein synthesis, as shown by pu-
romycin incorporation and by sustained phosphorylation
levels of Akt and p70. These kinases were shown to be un-
changed, or even up-regulated in the muscle of the C26
hosts,4,5 likely due to an attempt to counteract the tumour-
induced hypercatabolic drift. In this regard, the data reported
in the present study suggest that IL4 treatment is able to suc-
cessfully push forward such compensatory response. The ob-
servation that no changes in both protein synthesis and
anabolic kinase phosphorylation could be observed in IL4-
treated controls likely reflects the lack of effect in physiolog-
ical states, where protein metabolism is not altered. More-
over, IL4 treatment results in decreased phosphorylation of
some MAP kinases usually hyperactivated during cancer ca-
chexia and shown to play a role in promoting muscle protein
degradation.4,7 This last observation is as well supported by
lower levels of p62 accumulation in IL4-treated than IL4-
untreated C26 hosts.
Interleukin-4 administration to C26-bearing mice also re-
sults in decreased SC number, while a trend towards reduc-
tion can be observed in FAPs. These latter, however, show a
markedly reduced degeneration towards adipocyte-like cells
when isolated from the muscle of IL4-treated C26 hosts
and put in culture, supporting the idea that a restored
IL4/IL13 signalling can decrease the degeneration of muscle
stem cells in C26-bearing mice. These findings are in accor-
dance with the reduced muscle atrophy and fibrosis ob-
tained in mdx mice by preventing FAP degeneration.15,35
The delay in muscle regeneration occurring in the C26 hosts
is partially corrected by IL4 treatment, as shown by the in-
creased number of myofibers with central nuclei, that slowly
reach the mature phenotype, characterized by low expres-
sion of eMYHC. Interestingly, these fibres are not blocked
in their growth, but they rather undergo a temporary delay,
showing, after a longer time period, several fully matured fi-
bres with peripheral nuclei. In line with our results, a recent
study showed that IL4-conjugated gold nanoparticles
injected into injured murine skeletal muscle improved mus-
cle histology and performance associated with two-fold in-
crease of type II macrophages.36
The idea that IL4 treatment in the C26 hosts acts on the
muscle by stimulating myogenic differentiation, likely through
improved FAP activity, is supported by the results obtained
on C2C12 cultures exposed to the cytokine. Indeed, IL4 not
only is able to inhibit myoblast proliferation prompting them
to differentiation but also counteracts, partially at least, the
inhibition of differentiation induced by TNFα. In this regard,
TNFα maintains C2C12 cultures in a proliferative setting,37
which could partially explain the accumulation of SCs ob-
served in the muscle of tumour-bearing mice. Interestingly,
the inhibition of C2C12 differentiation by TNFα is associated
with reduced levels of IL4Ra. Thus, increasing IL4 concentra-
tions do not rescue MyHC levels. The ability of IL4 to guide
myogenesis is in line with previous data obtained in human
muscle cells.16,17 The involvement of IL4 in myogenesis is fur-
ther supported by the observation that loss of function of
both IL4Ra and IL13Ra during differentiation impairs the abil-
ity of myoblasts to fuse. As for the mechanisms by which the
lack of IL4-dependent signalling may inhibit differentiation,
down-regulation of Myomerger (ESGP) protein levels as well
as of other genes relevant to fusion has been shown to occur.
These results demonstrate that physiologic expression of
IL4Ra is necessary to determine myocyte fusion, in C2C12 cul-
tures at least, and it is not dispensable to complete myotube
differentiation.
A possible limitation in the present study is that in-
creased tumour mass occurs when IL4 is administered to
C26-bearing mice. In this regard, in colorectal cancer stem
cells, protection from apoptosis is achieved by autocrine
production of IL4 through up-regulation of anti-apoptotic
mediators.38 These observations could introduce a note of
care to the possibility that IL4 treatment can be proposed
as a strategy to counteract cancer cachexia. However,
despite being increased in size, tumours at Day 31 in
IL4-treated C26 hosts present with conspicuous necrotic
areas and with a high number of infiltrating
inflammatory/immune cells (CD8+ lymphocytes and type II
macrophages), which could be involved in tumour cytotoxic-
ity and necrosis. These results suggest that IL4
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administration to C26-bearing mice, far from stimulating
cancer growth, increases the immune response against the
tumour. However, this observation is in apparent contrast
with the well-known anti-inflammatory action of IL4. In this
regard, further experiments are required to clarify if sys-
temic IL4 administration might exert different actions at
the tumour and muscle levels, respectively. Consistently,
the observations here reported show that in vitro IL4 is able
to modulate myogenesis but not to affect C26 tumour cell
growth curve, suggesting that while the effects on muscle
are directly mediated by IL4, those on the tumour could de-
pend on additional mediators.
In conclusion, these results demonstrate the importance of
IL4 as a cytokine able to impinge on the inflammatory system,
promoting an anti-inflammatory muscle micro-environment,
and to raise the state of activation of anabolic kinases in-
volved in the maintenance of muscle protein synthesis. Of in-
terest, IL4 shares at least some beneficial actions with
exercise, previously shown to reduce systemic inflamma-
tion39 and to increase muscle protein synthesis.21 In this re-
gard, the hypothesis that IL4 could work as a sort of
exercise-mimetic drug could be proposed, although further
analyses aimed at assessing muscle energy metabolism after
IL4 administration are required to clarify this point. On the
whole, the results shown in the present study highlight that
IL4/IL13 signalling is effective in keeping the correct equilib-
rium between anabolic and catabolic cues. Physiologic levels
of IL4/IL13 are probably responsible for the normal homeo-
stasis of muscle tissue; when dysregulated, they can contrib-
ute to muscle atrophy. Further efforts should be performed
to determine if the administration of IL4 could ameliorate
cancer-induced muscle atrophy when associated to chemo-
therapeutic drugs and perhaps extend this treatment to
other disorders where muscle precursor accumulation occurs,
such as muscular dystrophies (at least in the initial phases of
the disease) or myotonic dystrophies, also characterized by
chronic inflammation.
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Figure S1: Characterization of C- and C26-SCs and MABs. a) IF
of SCs from C and C26 muscles stained for ACTN2 (red) and
MyoD (green; at day 2 of differentiation). Nuclei were stained
with HOECHST (blue). Scale bar: 500 μm. WB for MyHC and
aTub on b) GFP+ C- and c) GFP+ C26-MABs in co-culture with
C2C12 at day 0 and 5 of myotube differentiation. d) qRT-PCR
for the expression of IL4, IL4Ra1, IL13 and IL13R in C and C26
muscles normalized for the housekeeping genes Gapdh,
HPRT, TBP. Significance of the differences: *p < 0.05, ****p
< 0.0001 vs C.
Figure S2: IL4 treatment. a) C26 number of cells treated for
72 h in vitro with 10, 100 and 500 ng/ ml IL4. b) Absorption
curve of IL4 in Balb/c mice at different time points after 1.3
ug IL4 administration (n = 3 per time point). c) Tumor weight
in C26 and C26 + IL4 at the day of the sacrifice (14 days after
tumor cell injection; n = 4 per group). d) Quadriceps muscle
weight of C, IL4, C26 and C26 + IL4 mice (C: 410 ± 33
mg/100 g i. b. w.). Representative flow cytometry analysis
on cells extracted after peritoneal lavage from (e, h) 1
mg/kg LPS injected mice (as positive control), or C26 and
C26 + IL4 peritoneal lavage was analyzed for the main
markers of (f) lymphocytes and (g) quantified or for (i) macro-
phage populations and (j) quantified. Significance of the dif-
ferences **p < 0.01, ***p < 0.001, ****p < 0.0001 vs C; +
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+p < 0.01, +++p < 0.001 vs IL4; $p < 0.05, $$$p < 0.001 vs
C26.
Figure S3: Flow cytometry analysis of circulating immune
cells. Representative flow cytometry analysis of the circulat-
ing immune cells from C26 and C26 + IL4 mice for the main
markers and quantifications of (a) lymphocytes and (b) mac-
rophages. Significance of the differences $$$p < 0.001 vs
C26.
Figure S4: analysis of other important protein expressions in
muscle tissue. a) WB for p38 MAP-Kinase and (b) quantifica-
tion. c) WB for nuclear extract of P-STAT3 and P-STAT6 with
(d, e) respective quantifications. f) WB for Atrogin1 and
TRIM32 with (g, h) respective quantification. i) WB for
Beclin1, LC3B, p62 and (j - l) respective quantifications. m)
WB for the comparison of p62 levels between C26 and C26
+ IL4 and (n) quantification. All the values were normalized
for the total protein levels and on aTub or GAPDH expression
levels. Significance of the differences is reported as *p <
0.05, **p < 0.01, ***p < 0.001 vs C; ++p < 0.01, +++p <
0.001 vs IL4; $p < 0.05 vs C26.
Figure S5: Numbers of cells extracted from muscle of C, IL4,
C26 and C26 + IL4 normalized for the muscle mass. a) Cells
were counted immediately after tissue digestion. b) IF on
muscle slides for the expression of PDGFRa (green) and Ki67
(magenta) from C, IL4, C26, C26 + IL4 muscles. HOECHST
(blue) was used to stain nuclei. The arrows indicate double
positive nuclei surrounded by a green signal. *p < 0.05 vs
C; ++p< 0.01 vs IL4; $$$ p< 0.001 vs C26. Scale bar: 100 μm.
Figure S6: IL4-treated muscles do not show impairment in re-
generation after CTX injury. a) Average of fibre CSA in mus-
cles after 10 days of CTX injection. b) H&E staining of
muscle sections taken at longer time points after CTX injury
was induced. In particular, for CTX-C26 (n = 5), 9 to 12 days
after CTX injury, and for CTX-C26 + IL4 mice (n = 5), 16 to
30 days after CTX injury. Significance of the differences
***p < 0.001 vs C; +++p < 0.001 vs IL4; $$$p < 0.001 vs C26.
Figure S7: Increasing concentrations of IL4 dos not rescue 50
ng/ ml TNFa-impaired myotube differentiation. a) qRT-PCR
for the expression of IL4, IL4Ra, IL13 and IL13R in C2C12 at
day 0 and 5 of myotube differentiation normalized for the
housekeeping genes Gapdh, HPRT, TBP. b) C2C12 myoblasts
at day 2 of differentiation were analyzed for IL4R expression
on the levels of aTUB. c) MyHC levels by WB were normalized
for aTub and quantified in C2C12 treated with low concentra-
tion of TNFa (50 ng/ml) and (d) 100 ng/ ml IL4 or (e-f) 200
ng/ml IL4. g) Silencing for IL4R1a and (h) for IL13R1a in
myotubes was measured by qRT-PCR during the three last
days of differentiation (esi24h = day 3, esi48h = day 4, esi72h
= day 5 of differentiation medium). i) Levels of Myomixer
(Mymx), Myomaker (Mymk) and Myomerger (Gm7325s and
Gm7325l) were analyzed on the IL4R1a silenced cells by
qRT-PCR normalized for the housekeeping genes Gapdh,
HPRT, TBP. j) WB and (k) quantification for ESGP
(Myomerger) on the levels of GAPDH in CTX-C CTX-IL4, CTX-
C26 and CTX-C26 + IL4 muscle protein extract. Significance
of the differences *p < 0.05, **p < 0.01, ***p < 0.001,
****p < 0.0001 vs C; +p < 0.05, +++p < 0.001 vs IL4. £p <
0.05 vs CTX-C; ^p < 0.05 vs CTX-IL4.
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